Skip to main content
SpringerLink
Log in

Cost-Effectiveness Analysis in Cancer Care

  • Chapter
  • First Online:
Gastrointestinal Malignancies

Part of the book series: Cancer Treatment and Research ((CTAR))

Abstract

With the increasing complexity of modern medical therapies, it is becoming imperative to recognize the marginal cost and gains of increasingly sophisticated (and expensive) interventions. By understanding the incremental cost of a given intervention, investigators must help answer questions about healthcare resource utilization that are not answered by randomized clinical trials. The continued funding of biomedical research and pharmaceuticals will require more objective study of the return on investment for any given treatment modality, and cost-effectiveness analyses will be instrumental in providing solutions to the inequalities in healthcare delivery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Abbott DE, Sutton JM, Edwards MJ (2014) Making the case for cost-effectiveness research. J Surg Oncol 109(6):509–515

    Article  PubMed  Google Scholar 

  2. Tengs TO, Adams ME, Pliskin JS et al (1995) Five hundred life saving interventions and their cost-effectiveness. Risk Anal 15(3):369–390

    Article  CAS  PubMed  Google Scholar 

  3. Diamond GA, Kaul S (2009) Cost, effectiveness, and cost-effectiveness. Circ Cardiovasc Perspect 2:49–54

    Article  Google Scholar 

  4. Hadorn DC (1991) Setting health care priorities in oregon. Cost-effectiveness meets the rule of rescue. JAMA 265(17):2218–2225

    Article  CAS  PubMed  Google Scholar 

  5. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB (1996) Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276(15):1253–1258

    Article  CAS  PubMed  Google Scholar 

  6. Braithwaite RS, Meltzer DO, King JTJ, Leslie D, Roberts MS (2008) What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 46:349–356

    Article  PubMed  Google Scholar 

  7. Edejer TT, Baltussen R, Adam T et al (eds) (2003) WHO guide to cost-effectiveness analysis. World Health Organization, Switzerland

    Google Scholar 

  8. American Cancer Society (2014) Cancer facts and figures 2014. American Cancer Society, Atlanta

    Google Scholar 

  9. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63(1):11–30

    Google Scholar 

  10. Yeo CJ, Abrams RA, Grochow LB et al (1997) Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225(5):621–633

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Holbrook RF, Hargrave K, Traverso LW (1996) Prospective cost analysis of pancreatoduodenectomy. Am J Surg 171(5):508–511

    Article  CAS  PubMed  Google Scholar 

  12. Abbott DE, Merkow RP, Cantor SB et al (2012) Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement. Ann Surg Oncol 19(12):3659–3667

    Article  PubMed  Google Scholar 

  13. Abbott DE, Tzeng CW, Merkow RP et al (2013) The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol 20(3):500–508

    Article  Google Scholar 

  14. Evans DB, Pisters PW, Lee JE et al (1998) Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. J Hepatobiliary Pancreat Surg 5(3):242–250

    Article  CAS  PubMed  Google Scholar 

  15. Abu Hilal M, Hamdan M, Di Fabio F, Pearce NW, Johnson CD (2012) Laparoscopic versus open distal pancreatectomy: a clinical and cost-effectiveness study. Surg Endosc 26(6):1670–1674

    Google Scholar 

  16. Limongelli P, Belli A, Russo G et al (2012) Laparoscopic and open surgical treatment of left-sided pancreatic lesions: clinical outcomes and cost-effectiveness analysis. Surg Endosc 26(7):1830–1836

    Article  PubMed  Google Scholar 

  17. Rosales-Velderrain A, Bowers SP, Goldberg RF et al (2012) National trends in resection of the distal pancreas. World J Gastroenterol 18(32):4342–4349

    Article  PubMed  PubMed Central  Google Scholar 

  18. Birkmeyer JD, Siewers AE, Finlayson EVA et al (2002) Hospital volume and surgical mortality in the united states. N Engl J Med 346:1128–1137

    Article  PubMed  Google Scholar 

  19. Sutton JM, Wilson GC, Paquette IM et al (2014) Cost effectiveness after a pancreaticoduodenectomy: bolstering the volume argument. HPB 16(12):1056–1061

    Article  PubMed  PubMed Central  Google Scholar 

  20. Spanknebel K, Conlon KC (2001) Advances in the surgical management of pancreatic cancer. Cancer J 7(4):312–323

    CAS  PubMed  Google Scholar 

  21. Kent TS, Sachs TE, Callery MP, Vollmer CMJ (2013) The burden of infection for elective pancreatic resections. Surgery 153(1):86–94

    Article  PubMed  Google Scholar 

  22. Enestvedt CK, Diggs BS, Cassera MA, Hammill C, Hansen PD, Wolf RF (2012) Complications nearly double the cost of care after pancreaticoduodenectomy. Am J Surg 204(3):332–338

    Article  PubMed  Google Scholar 

  23. Pratt W, Maithel SK, Vanounou T, Callery MP, Vollmer CMJ (2006) Postoperative pancreatic fistulas are not equivalent after proximal, distal, and central pancreatectomy. J Gastrointest Surg 10(9):1264–1278

    Article  PubMed  Google Scholar 

  24. Rosenberg L, MacNeil P, Turcotte L (1999) Economic evaluation of the use of octreotide for prevention of complications following pancreatic resection. J Gastrointest Surg 3(3):225–232

    Article  CAS  PubMed  Google Scholar 

  25. Vanounou T, Pratt WB, Callery MP, Vollmer CMJ (2007) Selective administration of prophylactic octreotide during pancreaticoduodenectomy: a clinical and cost-benefit analysis in low- and high-risk glands. J Am Coll Surg 205(4):546–557

    Article  PubMed  Google Scholar 

  26. Allen PJ, Gonen M, Brennan M et al (2014) Pasireotide for postoperative pancreatic fistula. NEJM 370(21):2014–2022

    Article  PubMed  Google Scholar 

  27. Porter GA, Pisters PW, Mansyur C et al (2000) Cost and utilization impact of a clinical pathway for patients undergoing pancreaticoduodenectomy. Ann Surg Oncol 7(7):484–489

    Article  CAS  PubMed  Google Scholar 

  28. Glass CC, Gondek SP, Vollmer CMJ, Callery MP, Kent TS (2013) Readmission following pancreatectomy: what can be improved? HPB 15(9):703–708

    Article  PubMed  PubMed Central  Google Scholar 

  29. Reddy DM, Townsend CMJ, Kuo YF, Freeman JL, Goodwin JS, Riall TS (2009) Readmission after pancreatectomy for pancreatic cancer in medicare patients. J Gastrointest Surg 13(11):1963–1974

    Article  PubMed  PubMed Central  Google Scholar 

  30. Ahmad SA, Edwards MJ, Sutton JM et al (2012) Factors influencing readmission after pancreaticoduodenectomy: a multi-institutional study of 1302 patients. Ann Surg 256(3):529–537

    Article  PubMed  Google Scholar 

  31. Kent TS, Sachs TE, Callery MP, Vollmer CMJ (2011) Readmission after major pancreatic resection: a necessary evil? J Am Coll Surg 213(4):515–523

    Article  PubMed  Google Scholar 

  32. Holzman MD, Reintgen KL, Tyler DS, Pappas TN (1997) The role of laparoscopy in the management of suspected pancreatic and periamupllary malignancies. J Gastrointest Surg 1(3):236–244

    Article  CAS  PubMed  Google Scholar 

  33. Tzeng CW, Abbott DE, Cantor SB et al (2013) Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol 20(7):2197–2203

    Article  PubMed  Google Scholar 

  34. Gudjonsson B (1995) Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardizing reporting. J Am Coll Surg 181(6):483–503

    CAS  PubMed  Google Scholar 

  35. Ljungman D, Lundholm K, Hyltander A (2011) Cost-utility estimation of surgical treatment of pancreatic carcinoma aimed at cure. World J Surg 35(3):662–670

    Article  PubMed  Google Scholar 

  36. Tingstedt B, Andersson E, Flink A, Bolin K, Lindgren B, Andersson R (2011) Pancreatic cancer, healthcare cost, and loss of productivity: a register-based approach. World J Surg 35(10):2298–2305

    Article  PubMed  Google Scholar 

  37. Lansdorp-Vogelaar I, Knudsen AB, Brenner H (2011) Cost-effectiveness of colorectal cancer screening. Epidimiol Rev 33(1):88–100

    Article  Google Scholar 

  38. Qian MY, Yuwei JR, Angus P, Scheleman T, Johnson L, Gow P (2010) Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital. J Gastroenterol Hepatol 25(5):951–956

    Article  PubMed  Google Scholar 

  39. Bolondi L, Sofia S, Siringo S et al (2001) Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48(2):251–259

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Sangchan A, Chaiyakunapruk N, Supakankunti S, Pugkhem A, Mairiang P (2014) Cost utility analysis of endoscopic biliary stent in unresectable hilar cholangiocarcinoma: decision analytic modeling approach 61(113):1175–1181

    Google Scholar 

  41. Arguedas MR, Heudebert GH, Stinnett AA, Wilcox CM (2002) Biliary stents in malignant obstructive jaundice due to pancreatic carcinoma: a cost-effectiveness analysis. Am J Gastroenterol 97:898–904

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of Cincinnati, Cincinnati, USA

    Alex Chang

  2. Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

    Daniel E. Abbott

Authors
  1. Alex Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel E. Abbott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel E. Abbott .

Editor information

Editors and Affiliations

  1. Department of Surgery, Northwestern University, Chicago, Illinois, USA

    David Bentrem

  2. Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois, USA

    Al B. Benson

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Chang, A., Abbott, D.E. (2016). Cost-Effectiveness Analysis in Cancer Care. In: Bentrem, D., Benson, A. (eds) Gastrointestinal Malignancies. Cancer Treatment and Research. Springer, Cham. https://doi.org/10.1007/978-3-319-34244-3_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-34244-3_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-34242-9

  • Online ISBN: 978-3-319-34244-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation